Clinical trial
Three Modalities of Treatment in Operable and Resectable Stage IIIA (T1-3, N2)…
NCT00198367 · Hospices Civils de Lyon, Other · Completed
Key facts
| NCT number | NCT00198367 |
|---|---|
| Title | Three Modalities of Treatment in Operable and Resectable Stage IIIA (T1-3, N2) Non-Small Cell Lung Cancer (NSCLC) |
| Official title | Three Modalities of Treatment in Operable and Resectable Stage IIIA (T1-3, N2) NSCLC. Randomized Phase II Study |
| Lead sponsor | Hospices Civils de Lyon, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Non-small Cell Lung Cancer |
| Intervention type | Drug |
| Interventions | Cisplatin-Gemzar, Cisplatin-Navelbine-Radiotherapy, Carboplatin-Taxol-Radiotherapy |
| Enrollment | 120 |
| Start date | Jan 1, 2003 |
| Primary completion | Jan 1, 2008 |
| Completion | Jul 1, 2012 |
| First posted | Sep 20, 2005 |
| Last update posted | May 28, 2019 |
| Countries | France |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: